Lp(a) falls sharply in trial, but heart events did not

A closely watched cardiovascular trial has added a wrinkle to the race to treat lipoprotein(a), often shortened to Lp(a). In a large phase 3 study of pelacarsen, the drug lowered Lp(a) substantially, but that reduction did not translate into fewer major heart-related events during the study period.

The results matter because Lp(a) has long been viewed as a promising target in heart disease prevention. But they also show that lowering a blood marker does not always lead to better clinical outcomes, especially when a therapy is tested in people who already have established cardiovascular disease.

What happened in the trial

The study, called Lp(a) HORIZON, evaluated pelacarsen in adults with elevated Lp(a) and existing cardiovascular disease. According to the American Heart Association’s summary of the trial, pelacarsen lowered Lp(a) by 78% compared with placebo. The trial’s main cardiovascular outcome, however, did not improve. Major adverse cardiovascular events in this study included nonfatal heart attack, nonfatal stroke, urgent coronary revascularization, or death from cardiovascular causes.

Coverage from STAT reported the same overall message: the drug sharply lowered Lp(a) but did not reduce heart attacks, strokes, urgent revascularization procedures, or deaths in the study population. A JAMA news summary of the presentation likewise described the trial as neutral for cardiovascular outcomes despite the biomarker drop.

Why Lp(a) has attracted so much attention

Lp(a) is a cholesterol-carrying particle in the blood that is largely inherited. The American Heart Association says every adult should be tested at least once in their lifetime, and it notes that higher levels are linked with greater risk of heart disease and stroke. Research reviews indexed in PubMed describe Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease and, in some evidence, ischemic stroke and aortic valve disease.

That background helps explain why drug developers have been pursuing medicines that can lower Lp(a) much more directly than standard cholesterol treatments do. Pelacarsen is one of the most advanced of those candidates. Earlier research had shown that it could drive Lp(a) down markedly, which made the phase 3 outcome trial an important test of whether the biomarker change would matter clinically.

What the evidence actually shows

The strongest conclusion from this trial is narrow but important: in the studied population, lowering Lp(a) with pelacarsen did not reduce the composite rate of major cardiovascular events over the follow-up period reported so far. That does not mean Lp(a) is unimportant, and it does not prove that all Lp(a)-lowering therapies will fail. It does show that the relationship between Lp(a) reduction and clinical benefit is more complicated than many clinicians and researchers hoped.

One possible reason is that the people enrolled in the trial already had cardiovascular disease, so their event risk was influenced by many other factors besides Lp(a). Another possibility is that the trial duration, event mix, or degree of Lp(a) lowering was not enough to show benefit, even though the biomarker response was strong. Those are interpretations, not settled facts, and they are part of why the results are being scrutinized closely.

What remains uncertain

Several questions remain open. It is not yet clear whether a different Lp(a)-targeting approach, a different dose, a different population, or earlier treatment could produce a different outcome. It is also not yet clear whether some patients with very high Lp(a) levels might benefit in ways not captured by the main trial endpoint.

Another uncertainty is how to use these results in everyday care. The trial does not change the fact that Lp(a) is a meaningful risk marker. But it does suggest that simply lowering Lp(a) is not, by itself, enough proof that a drug will prevent heart attacks or strokes. In cardiovascular medicine, that distinction matters: a biomarker change can be encouraging, but it is not the same as demonstrating fewer clinical events.

How this fits into current heart-risk care

For now, people found to have high Lp(a) are generally managed by addressing the risk factors that do have proven benefit. That usually means making sure blood pressure, LDL cholesterol, diabetes, smoking status, physical activity, and other modifiable risks are being managed as well as possible. The American Heart Association notes that overall risk depends on more than Lp(a) alone.

Because elevated Lp(a) often has no symptoms, the result is typically discovered through a blood test rather than from how a person feels. Anyone who has already had a heart attack, stroke, or other cardiovascular event and is concerned about inherited risk should discuss Lp(a) testing and broader prevention strategies with a clinician. People with chest pain, shortness of breath, sudden weakness, trouble speaking, or other possible emergency symptoms should seek urgent medical care right away.

What readers should take away

This trial is an important setback for one strategy, not the end of Lp(a) research. It adds evidence that lowering a promising risk marker does not automatically improve outcomes, and it highlights why cardiovascular drug development still depends on hard clinical endpoints such as heart attacks, strokes, and death.

For patients, the practical message is steadier than the headline: Lp(a) remains a legitimate risk factor, but there is not yet a dedicated treatment proven to reduce events by targeting it alone. The best-supported approach today is to control overall cardiovascular risk while researchers continue testing newer therapies.